Hemostemix (CVE:HEM) Trading 29.4% Higher – Time to Buy?

Hemostemix Inc. (CVE:HEM) shares rose 29.4% during mid-day trading on Friday . The stock traded as high as C$0.11 and last traded at C$0.11. Approximately 602,760 shares traded hands during trading, an increase of 511% from the average daily volume of 98,700 shares. The stock had previously closed at C$0.09.

Hemostemix Stock Performance

The stock’s 50 day moving average price is C$0.09 and its 200 day moving average price is C$0.10. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The firm has a market cap of C$20.73 million, a PE ratio of -4.07 and a beta of 1.25.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.